XBiotech Inc. (NASDAQ:XBIT) rolled off 40.04% or $6.82 to $10.20 per share on April 21, after announcing that its marketing authorization application (MAA) related to its candidate antibody for treating colorectal cancer received a negative “trend” vote from the European Medicines Agency (EMA). “We…
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
April 21, 2017 at 07:38PM
from Kristine Espinoza
No comments:
Post a Comment